Jazz Pharmaceuticals (JAZZ) Receivables (2010 - 2026)

Jazz Pharmaceuticals' Receivables history runs 17 years deep, the most recent figure standing at $836.3 million for Q1 2026.

• On a quarterly basis, Receivables rose 28.07% year-over-year to $836.3 million in Q1 2026; TTM through Mar 2026 was $836.3 million, a 28.07% increase from a year earlier, with the FY2025 full-year figure at $830.7 million, up 15.9% from the prior year.
• Receivables rose to $836.3 million in Q1 2026 per JAZZ's latest filing, from $830.7 million in the prior quarter.
• Across five years, Receivables topped out at $836.3 million in Q1 2026 and bottomed at $572.4 million in Q1 2022.
• The 5-year median for Receivables is $698.0 million (2024), against an average of $684.2 million.
• Across the five-year window, Receivables surged 38.27% in 2022 and dropped 7.65% in 2025, its largest moves.
• Year by year, Receivables stood at $651.5 million in 2022, then climbed by 8.33% to $705.8 million in 2023, then advanced by 1.55% to $716.8 million in 2024, then climbed by 15.9% to $830.7 million in 2025, then advanced by 0.67% to $836.3 million in 2026.
• Per Business Quant, the three latest JAZZ Receivables figures stand at $836.3 million (Q1 2026), $830.7 million (Q4 2025), and $764.4 million (Q3 2025).